

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-----------------------|
| Application Number | 10/045,180 |
| Filing Date | October 18, 2001 |
| First Named Inventor | Lydie Bougueleret |
| Art Unit | 1645 1644 |
| Examiner Name | Unassigned VanderVest |
| Attorney Docket Number | GEN-100D1 |

Sheet

1

of

3

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|---|--------------------------------|--|---|
| R | U1 | US- 5,242,902 | 09-07-1993 | Murphy et al. | All |
| R | U2 | US- 5,841,497 | 08-24-1997 | Bevins et al. | All |
| | U3 | US- | | | |
| | U4 | US- | | | |
| | U5 | US- | | | |
| | U6 | US- | | | |
| | U7 | US- | | | |
| | U8 | US- | | | |
| | U9 | US- | | | |
| | U10 | US- | | | |
| | U11 | US- | | | |
| | U12 | US- | | | |
| | U13 | US- | | | |
| | U14 | US- | | | |
| | U15 | US- | | | |
| | U16 | US- | | | |
| | U17 | US- | | | |
| | U18 | US- | | | |
| | U19 | US- | | | |
| | U20 | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|--------------------|-----------------------|--|--------------------------------|--|---|----------------|
| R | F1 | WO 89/11291 | 11-30-1989 | Invitron Corp. | All | |
| | F2 | WO 94/21672 | 09-28-1994 | Regents of U. of Calif. | All | |
| | F3 | WO 95/32287 | 11-30-1995 | Magalnin Pharmaceuticals | All | |
| | F4 | | | | | |
| | F5 | | | | | |
| | F6 | | | | | |
| | F7 | | | | | |
| | F8 | | | | | |
| | F9 | | | | | |
| | F10 | | | | | |

| | | | |
|--------------------|--|-----------------|----------|
| Examiner Signature | | Date Considered | 12/16/05 |
|--------------------|--|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.





PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 10/045,180 |
| Filing Date | October 18, 2001 |
| First Named Inventor | Lydie Bougueleret |
| Group Art Unit | 1645-1644 |
| Examiner Name | Unassigned VanderVegte |
| Attorney Docket Number | GEN-100D1 |

Sheet 2 of 3

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| A | R1 | BEVINS, et al. [1996] "Human Enteric Defensin Genes: Chromosomal Map Position and a Model for Possible Evolutionary Relationship", <i>Genomics</i> , 31:95-106 | |
| | R2 | GANZ et al. [1994] "Defensins", <i>Current Opinion in Immunology</i> , 6:584-589 | |
| | R3 | GANZ et al. [1995] "Defensins", <i>Pharmac Ther.</i> , 66:191-205 | |
| | R4 | HUGHES, A. [1999] "Evolutionary Diversification of the Mammalian Defensins", <i>CMLS, Cell. Mol. Life Sci.</i> 56:94-103 | |
| | R5 | HUGHES, A. et al. [1997] "Coordinated Amino Acid Changes in the Evolution of Mammalian Defensins", <i>J. Mol. Evol.</i> 44:675-82 | |
| | R6 | KAGAN et al. [1994] "Defensins: a Family of Antimicrobial and Cytotoxic Peptides", <i>Toxicology</i> , 87:131-149 | |
| | R7 | LEHRER et al. [1992] "Defensins: Endogenous Antibiotic Peptides from Human Leukocytes", <i>Giba Foundation Symposium</i> 171:276-293 | |
| | R8 | LERNER R. [1982] "Tapping the Immunological Repertoire to Produce Antibodies of Predetermined Specificity", <i>Nature</i> 299:592-96 | |
| | R9 | MALLOW et al. [1996] "Human Enteric Defensins", <i>The Journal of Biological Chemistry</i> 271:4038-4045 | |
| | R10 | MARTIN et al. [1995] "Defensins and Other Endogenous Peptide Antibiotics of Vertebrates", <i>Journal of Leukocyte Biology</i> 58:128-136 | |
| | R11 | RAJ, P. [2000] "Large-scale Synthesis and Functional Elements for the Antimicrobial Activity of Defensins", <i>Biochem. J.</i> 347:633-41 | |
| | R12 | SPARKES et al. [1989] "Assignment of Defensin Gene(s) to Human Chromosome 8p23", <i>Genomics</i> 5:240-244 | |
| | R13 | WHITE et al. [1995] "Structure, Function, and Membrane Integration of Defensins", <i>Current Opinion in Structural Biology</i> 5:521-527 | |


| | | | |
|--------------------|--|-----------------|----------|
| Examiner Signature | | Date Considered | 12/16/05 |
|--------------------|--|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

+

| | | | | | |
|---|---|--------------------------|-----------------------|------------------------|-----------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/045,180 | | |
| | | Filing Date | October 18, 2001 | | |
| | | First Named Inventor | Lydie Bougueleret | | |
| | | Group Art Unit | 1645 1644 | | |
| | | Examiner Name | Unassigned Vanderkast | | |
| Sheet | 3 | of | 3 | Attorney Docket Number | GEN-100D1 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| R | R14 | WILDE et al. [1989] "Purification and Characterization of Human Neutrophil Peptide 4, a Novel Member of the Defensin Family", <i>Journal of Biological Chemistry</i> 264 (19):11200-11203 | |
| | R15 | | |
| | R16 | | |
| | R17 | | |
| | R18 | | |
| | R19 | | |
| | R20 | | |
| | R21 | | |
| | R22 | | |
| | R23 | | |
| | R24 | | |
| | R25 | | |
| | R26 | | |

| | | | |
|--------------------|--|-----------------|----------|
| Examiner Signature | | Date Considered | 12/16/05 |
|--------------------|--|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

+

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.